Roche’s 2025 profit blunted by weakened US dollar

Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the drugmaker reporting strong growth for food allergy medicine Xolair (omalizumab) and multiple sclerosis treatment Ocrevus (ocrelizumab). Core operating profit reached SFr21.8bn ($28.4bn) for the Swiss big pharma company in 2025, slightly down from a market consensus of SFr22bn cited by analysts. Total sales for Roche came in at SFr61.5bn, a 7% change at constant exchange rates (CER). Thi ...